Today’s Stocks: BioPharmX Corporation (NYSEMKT:BPMX), Allegheny Technologies Inc. (NYSE:ATI), Aratana Therapeutics, Inc. (NASDAQ:PETX), CSX Corp. (NYSE:CSX), Tredegar Corp. (NYSE:TG)

BioPharmX Corporation (NYSEMKT:BPMX) belongs to Healthcare sector. weekly performance is -0.85%. On last trading day company shares ended up $2.34. BioPharmX Corporation (NYSEMKT:BPMX) distance from 50-day simple moving average (SMA50) is -24.72%. BioPharmX Corporation (NYSE MKT: BPMX), is pleased to announce that the company’s chief executive officer and its president are invited by the New York Stock Exchange (NYSE) to ring the NYSE Opening Bell® on Wednesday, July 15, 2015 to celebrate its listing. Its stock was uplisted and commenced trading on June 25, 2015.

Allegheny Technologies Inc. (NYSE:ATI) belongs to Industrial Goods sector. Its net profit margin is 0.60% and weekly performance is -1.57%. On last trading day company shares ended up $28.16. Allegheny Technologies Inc. (NYSE:ATI) distance from 50-day simple moving average (SMA50) is -14.09%. Allegheny Technologies Inc. (NYSE:ATI) said Tuesday that it expects to report a net loss attributable to company of $16 to $18 million, or $0.15 to $0.17 per share, for the second quarter, due mainly to challenging business conditions in its Flat Rolled Products business and further weakening in demand from the oil and gas market. Analysts polled by Thomson Reuters currently expect the company to earn $0.20 per share for the second quarter. Analysts’ estimates typically exclude special items. The company said its second quarter performance continued to be pressured by the ATI Flat Rolled Products segment, which recorded its sixth quarterly operating loss over the last eight quarters.

Aratana Therapeutics, Inc. (NASDAQ:PETX) shares advanced 1.33% in last trading session and ended the day at $16.77. PETX Gross Margin is 28.60% and its return on assets is -19.00%. Aratana Therapeutics, Inc. (NASDAQ:PETX) quarterly performance is 4.03%. Aratana Therapeutics, Inc. (NASDAQ:PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced positive results from its pivotal field effectiveness study of AT-003, the company’s innovative drug for treating post-surgical pain in dogs. AT-003 is an extended-release bupivacaine liposome injectable suspension licensed from Pacira Pharmaceuticals, Inc. (PCRX).

On 14 July, CSX Corp. (NYSE:CSX) shares advanced 0.53% and was closed at $32.07. CSX EPS growth in last 5 year was 15.10%. CSX Corp. (NYSE:CSX) year to date (YTD) performance is -10.62%. On 14 July, CSX Corp. (NYSE:CSX) reported a higher quarterly net profit, beating forecasts as productivity gains and lower fuel prices offset a drop in coal volumes that took a bite out of revenue. CSX said coal revenue for the quarter fell 15 percent, contributing to an overall sales decline of 6 percent. The company said it expects coal volumes to be down approximately 10 percent for the full year.

Tredegar Corp. (NYSE:TG) shares moved up 0.71% in last trading session and ended the day at $22.74. TG Gross Margin is 14.60% and its return on assets is 4.80%. Tredegar Corp. (NYSE:TG) quarterly performance is 7.79%. Tredegar Film Products, a subsidiary of Tredegar Corp. (NYSE:TG) announced that it will invest in new assets to provide European customers with local supply of unique, state-of-the-art elastic laminates and elastic films for personal care applications. In response to increased demand for elastic products for adult incontinence and baby care applications, the Company is investing in new technology and capacity in the Rétság, Hungary plant to enable production of its FlexAireTM and ExtraflexTM products. The Company expects this additional capacity to be fully operational by the end of 2016.

Leave a Reply

Your email address will not be published. Required fields are marked *